Tumor necrosis factor-α: A continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review)

Medical Hypotheses

Volumn 52, Issue 4, 1999, Pages 319-323

  Holden, R J ^a   Pakula, I S ^b   Mooney, P A ^c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b South Eastern Sydney and Illawarra Area Health Service   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; CARCINOMA; CELL DESTRUCTION; CELL PROLIFERATION; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033019843     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0008     Document Type: Article

References (55)

1. Mehta V. K., Hao W., Brooks-Worrell B. M., Palmer J. P. Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol. 130:1994;208-214.
2. Jhala U., Baly D. L. Effect of chronic IL-1 beta infusion on glucose homeostasis and pancreatic insulin secretion. Life Sci. 54:1994;413-422.
3. Arias-Díaz J., Vara E., Gómez M., García C., Moreno A., Balibrea J. L. Effect of cytokines on 'de novo' lipid synthesis and hormone secretion by isolated human islets. Transplant Proc. 24:1992;2909-2912.
4. Vara E., Arias-Díaz J., García C., Balibrea J. L. Cytokine-induced inhibition of lipid synthesis and hormone secretion by isolated human islets. Pancreas. 9:1994;316-323.
5. Eizirik D. L., Sandler S., Welsh N. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest. 93:1994;1968-1974.
6. Kenner K. A., Hill D. E., Olefsky J. M., Kusari J. Regulation of protein tyrosine phosphatases by insulin and insulin-like growth factor I. J Biol Chem. 268:1993;25455-25462.
7. Tahiri-Jouti N., Cambillau C., Viguerie N. Characteriiation of a membrane tyrosine phosphatase in AR42J cells: regulation by somatostatin. Am J Physiol. 262:1992;G1007-G10014.
8. Goldstein B. J. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor. 3:1993;1-15.
9. Kulas D. T., Zhang W. R., Goldstein B. J., Furlanetto R. W., Mooney R. A. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem. 270:1995;2435-2438.
10. Singh S., Aggarwal B. B. Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B. J Biol Chem. 270:1995;10631-10639.
11. Drew P. D., Lonergan M., Goldstein M. E., Lampson L. A., Ozato K., McFarlin D. E. Regulation of MHC class I and beta 2-microglobulin gene expresslon in human neuronal cells. Factor binding to conserved cis-acting regulatory, sequences correlates with expression of the genes. J Immunol. 150:1993;3300-3310.
12. Drew P. D., Franzoso G., Carlson L. M., Biddison W. E., Siebenlist U., Ozato K. Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin gene expression in transfected human neuroblastoma cells. J Neuroimmunol. 63:1995;157-162.
13. Faustman D., Li X., Lin H. Y. Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science. 254:1991;1756-1830.
14. Hotamisligil G. S., Johnson R. S., Distel R. J., Ellis R., Papaioannou V. E ., Spiegelman B. M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 274:1996;1377-1379.
15. Hotamisligil G. S., Peraldi P., Budavari A., Ellis R., White M. F., Spiegelman B. M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 271:1996;665-668.
16. Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 95:1995;2409-2415.
17. Hotamisligil G. S., Budavari A., Murray D., Spiegelman B. M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 94:1994;1543-1549.
18. Hotamisligil G. S., Spiegelman B. M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
19. Hotamisligil G. S., Murray D. L., Choy L. N., Spiegelman B. M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA. 91:1994;4854-4858.
20. Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
21. Cavallo M. G., Baroni M. G., Toto A. Viral infection induces cytokine release by beta islet cells. Immunology. 75:1992;664-668.
22. Brouhard B. H. Cytokines and the pathogenesis of insulin-dependent diabetes mellitus. Cleveland Clin J Med. 59:1992;629-632.
23. Yamada K., Takane N., Otabe S., Inada C., Inoue M., Nonaka K. Pancreatic beta-cell-selective production of tumor necrosis factor-alpha induced by interleukin-1. Diabetes. 42:1993;1026-1031.
24. Meyerovitch J., Backer J. M., Kahn C. R. Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. J Clin Invest. 84:1989;976-983.
25. Itoh N., Hanafusa T., Miyazaki A. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest. 92:1993;2313-2322.
26. Demaine A. G., Hibberd M. L., Mangles D., Millward B. A. new marker in the HLA class I region is associated wi the age at onset of IDDM. Diabetologia. 38:1995;623-628.
27. Rothe H., Ongoren C., Martin S., Rosen P., Kolb H. Abnormal TNF-alpha production in diabetes-prone BB rats: enhanced TNF-alpha expression and defective PGE2 feedback inhibition. Immunology. 81:1994;407-413.
28. Baldwin R. L., Stolowitz M. L., Hood L., Wisnieski B. J. Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation. Proc Natl Acad Sci USA. 93:1996;1021-1026.
29. Kusari J., Kenner K. A., Suh K. I., Hill D. E., Henry R. R. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. J Clin Invest. 93:1994;1156-1162.
30. Fu Y., Nathan D. M., Li F., Li X., Faustman D. L. Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. J Clin Invest. 91:1993;2301-2307.
31. Gaits F., Li R. Y., Ragab A., Selves J., Ragab-Thomas J. M., Chap H. Implication of a protein-tyrosine-phosphatase in human lung cancer. Cell Mol Biol (Noisy-le-grand). 40:1994;677-685.
32. Mishra S., Hamburger A. W. Role of intracellular Ca2+ in the epidermal growth factor induced inhibition of protein tyrosine phosphatase activity in a breast cancer cell line. Biochem Biophys Res Commun. 191:1993;1066-1072.
33. Freiss G., Vignon F. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol. 8:1994;1389-1396.
34. Sridhar T. S., Swarup G., Khar A. Downregulation of phospho-tyrosine phosphatases in a macrophage tumor. FEBS Lett. 326:1993;75-79.
35. Verschuur H. P., Wynne H. J., Slootweg P. J. Clinical relevance of proteip tyrosine (de-)phosphorylation in head and neck cancer. Laryngoscope. 105:1995;1238-1244.
36. Parks R. R., Yan S. D., Huang C. C. Tumor necrosis factor-alpha production in human head and neck squamous cell carcinoma. Laryngoscope. 104:1994;860-864.
37. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer. 70:1992;709-713.
38. Restifo N. P., Marincola F. M., Kawakami Y., Taubenberger J., Yannelli J. R., Rosenberg S. A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 88:1996;100-108.
39. Végh Z., Wang P., Vánky F., Klein E. Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. Cancer Res. 53:1993;2416-2420.
40. Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A. L., Gatter K. C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 73:1996;148-153.
41. Ye X., Kralli A., Ge R., Ricciardi R. P., Knowles B. B. Down-regulation of MHC class I antigen in insulinoma cells controlled by the R1 element of the H-2 enhancer. Oncogene. 9:1994;1195-1204.
42. Jakobsen M. K., Restifo N. P., Cohen P. A. Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol. 17:1995;222-228.
43. Petersen B. L., Petersen C. L., Braendstrup O. Expression of beta 2-microglobulin by premalignant epithelium. APMIS. 101:1993;529-536.
44. Bours V., Dejardin E., Goujon-Letawe F., Merville M. P., Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol. 47:1994;145-149.
45. Zanker K. S., Kroczek R. Looking along the track of the psychoneuroimmunologic axis for missing links in cancer progression. Int J Sports Med. 12:1991;S58-62.
46. Xu C. T., Pan B. R., Wang Y. M. [Study on the peptides of serum and gastric juice in patients with gastric cancer]. Chung Hua I Hsueh Tsa Chih Taipei. 52:1993;32-35.
47. Kita T., Kikuchi Y., Oomori K., Nagata I. Effects of opioid peptides on the tumoricidal activity of spleen cells from nude mice with or without tumors. Cancer Detect Prev. 16:1992;211-214.
48. Pasi A., Amsler U., Messiha F. S. Beta-endorphin-like immunoreactivity: assessment of blood levels in patients with tumors of different origin. J Med. 22:1991;327-337.
49. Darko D. F., Irwin M. R., Risch S. C., Gillin J. C. Plasma beta-endorphin and natural killer cell activity in major depression: a preliminary study. Psychiatry Res. 43:1992;111-119.
50. Czlonkowski A., Stein C., Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol. 242:1993;229-235.
51. Moore R., Mills I. H., Forster A. Naloxone in the treatment of anorexia nervosa: effect on weight gain and lipolysis. J R Soc Med. 74:1981;129-131.
52. Atkinson R. L. Naloxone decreases food intake in obese humans. J Clin Endocrinol Metab. 55:1982;196-198.
53. Holden R. J., Pakula I. S. The role tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity. Med Hypotheses. 47:1996;423-438.
54. Rakowicz-Szulczynska E. M., McIntosh D. G., Smith M. Growth factor-mediated mechanisms of nicotine-dependent carcinogenesis. Carcinogenesis. 15:1994;1839-1846.
55. Jobe L. W., Vertrees S., Wilson C. A. In vivo effects of interleukin-l beta on blood leukocytes in BB rats prone or resistant to diabetes. Autoimmunity. 11:1992;233-237.